bpv Huegel advised Valneva SE in its successful $85 Million Financing Arrangement with Leading US Healthcare Funds

18 March 2020. bpv Huegel advised Valneva Austria GmbH, Vienna, in its debt financing transaction with funds managed by leading US-based healthcare investment firms. Both firms are providing their financing to support Valneva’s long-term strategy.

The transaction includes an initial fixed rate straight debt of $60 million and flexible terms that allow the company to draw down an additional $25 million of capital upon similar terms in the next 12 months. Completion took place in the beginning of March and included the perfection of liens and pledges over the main assets of Valneva Austria and subsidiaries of the Valneva Group.

Please also see the press release of Valneva SE: https://valneva.com/press-release/valneva-announces-new-85-million-financing-arrangement-with-leading-us-healthcare-funds-deerfield-and-orbimed/

Valneva SE is a biotech company developing and commercialising vaccines for infectious diseases with major unmet needs. Valneva SE’s portfolio includes two commercial vaccines for travellers: IXIARO®/JESPECT® indicated for the prevention of Japanese encephalitis and DUKORAL® indicated for the prevention of cholera and, in some countries, prevention of diarrhoea caused by ETEC. The Company has various vaccines in development including a unique vaccine against Lyme disease. Valneva SE has operations in Austria, Sweden, the United Kingdom, France, Canada and the US.

bpv Huegel`s team was led by Stefan Gaug (partner, finance/M&A) and Elke Napokoj (partner, M&A/capital market) and included Gerald Schachner (partner, tax), Sonja Dürager (partner, IP), Nicolas Wolski (senior associate, tax), David Pukel (associate, finance/M&A). bpv Huegel’s finance team is regularly involved in high profile finance transactions. bpv recently advised Valneva SE in its delisting from the Vienna Stock Exchange.

Dechert LLP acted as transaction counsel to Valneva in this transaction. Dorda, Vienna, acted as local counsel to the lender.

 

Press release

© 2026 bpv Hügel Rechtsanwälte

Our use of cookies

We use necessary and functionality cookies to make our site work. We only use analytics cookies to improve our website if you enable them. By using this tool for individual settings of the cookies, we will send a cookie to your device to remember your preferences.

For more detailed information about the cookies we use, see our Cookies Policy.

Necessary Cookies Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect the website functions.

Functionality Cookies

Functionality cookies allow users to customise how a website looks for them: they can remember usernames, language preferences and regions. We use functionality cookies for storing your user preferences and remembering if you have been to the site before so that messages intended for first-time users are not displayed to you. These cookies do not collect information about you that could be used for marketing purposes and do not remember where you have been on the Internet.

You may disable these cookies with the button, but you should be aware that any preferences will be lost and you will have to make them again on your next visit. It is also possible that the website will not work properly or you will lose some functionality.

Analytics cookies (including US providers)

"Web analytics cookies" collect aggregated information about user behaviour to improve our website. We would like to use such cookies from Google Analytics to improve our website by collecting and evaluating information about the use of our website. The provider of Google Analytics is Google LLC, which is based in the USA. The USA is not certified by the European Court of Justice as having an adequate level of data protection. In particular, there is a risk that your data may be accessed by US authorities for control and monitoring purposes and that no effective legal remedies are available against this. By activating the button under "Web analytics cookies (including from US providers)", you agree that we may set these cookies and that you also agree to the transfer of data to the USA. You can revoke your consent at any time via the cookie settings on our website.